Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perazine for schizophrenia.

S Leucht1, B Hartung

  • 1Psychiatrische Klinik und Poliklinik der Technischen Universität München Klinikum rechts der Isar, Ismaningerstr. 22, München, Germany, D-81675. stefan.leucht@lrz.tu-muenchen.de

The Cochrane Database of Systematic Reviews
|March 1, 2002
PubMed
Summary
This summary is machine-generated.

Perazine, an old antipsychotic for schizophrenia, shows limited evidence of efficacy and safety due to small, poorly reported trials. Further research is needed to confirm its side-effect profile compared to newer treatments.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[(Failed) Intubation during emergency coniotomy by the emergency physician].

Die Anaesthesiologie·2026
Same author

Cannabis in road traffic - a retrospective analysis to identify possible cut-off-values.

Forensic science, medicine, and pathology·2025
Same author

Parking behaviour under the influence of alcohol.

International journal of legal medicine·2023
Same author

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Translational psychiatry·2022
Same author

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2021
Same author

Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis.

Acta psychiatrica Scandinavica·2020
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Area of Science:

  • Psychiatry and Clinical Neuroscience
  • Pharmacology and Drug Development
  • Evidence-Based Medicine

Background:

  • Perazine is a phenothiazine derivative used for schizophrenia treatment, with a reputation for low extrapyramidal side-effects.
  • Its availability is limited, primarily marketed in Germany, Poland, Yugoslavia, and the Netherlands.

Purpose of the Study:

  • To evaluate the efficacy and safety of perazine in treating schizophrenia and schizophrenia-like psychoses.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through extensive electronic database searches and expert contact.
  • Included RCTs compared perazine with other treatments for schizophrenia.
  • Data extraction and quality assessment were performed independently by two reviewers, with meta-analysis conducted where data allowed.

Main Results:

  • Six trials involving 288 participants were included. Perazine showed a potential benefit over active placebo (trimipramine) for global improvement in one trial, but no significant differences in mental state measures.
  • Limited data from five trials (193 participants) comparing perazine with other antipsychotics suggested similar rates of study withdrawal.
  • While meta-analysis was often not possible due to incomplete reporting, perazine did not appear to have a higher risk of specific extrapyramidal side-effects (akathisia, dyskinesia, parkinsonism, tremor) compared to zotepine and amisulpride.

Conclusions:

  • The current body of evidence from RCTs on perazine is insufficient to draw firm conclusions regarding its efficacy and safety.
  • Larger, well-designed trials are necessary to definitively assess perazine's properties, particularly its risk of extrapyramidal side-effects in comparison to atypical antipsychotics.